[18F]FTT Positron Emission Tomography/Computed Tomography to Predict Treatment Response in Patients Scheduled to Receive Gemcitabine, Cisplatin, and Durvalumab for Newly Diagnosed Cholangiocarcinoma

NCT07673341 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

22

Enrollment

OTHER

Sponsor class

Conditions

Cholangiocarcinoma

Interventions

PROCEDURE: Computed Tomography
RADIATION: Fluorine F 18 Fluorthanatrace
PROCEDURE: Magnetic Resonance Imaging
PROCEDURE: Positron Emission Tomography

Sponsor

University of Washington